|
Oct. 29, 2021 |
|
|
Feb. 05, 2022 |
|
|
jRCT2032210400 |
Examination of the safety and the efficacy for patients using NP037 with chronic pain |
|
Examination of the safety and the efficacy for patients using NP037 with chronic pain |
Kondo Masako |
||
Nipro Corporation |
||
3023, Nojicho, Kusatsu, Shiga, JAPAN |
||
+81-77-564-0500 |
||
kondo-masako@nipro.co.jp |
||
Kondo Masako |
||
Nipro Corporation |
||
3023, Nojicho, Kusatsu, Shiga, JAPAN |
||
+81-77-564-0500 |
||
kondo-masako@nipro.co.jp |
Complete |
Nov. 01, 2021 |
||
| Nov. 08, 2021 | ||
| 50 | ||
Interventional |
||
non-randomized controlled trial |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
Patients aged >=20 years at the time of consent, etc. |
||
Patients whom an investigator or a sub-investigator judged to have difficulty in trial enforcement, etc. |
||
| 20age old over | ||
| No limit | ||
Both |
||
Chronic pain |
||
Put on a probe of NP037 in the pain site and treatment. |
||
Changes in VAS from first use to the end of the first use |
||
| Nipro Corporation |
| Review Board of Human Rights and Ethics for Clinical Studies Institutional Review Board | |
| 2-2-1, Kyobashi, Chuo-ku, Tokyo | |
+81-3-5123-0028 |
|
| soudan@hurecs.org | |
| Approval | |
Oct. 29, 2021 |
No |
none |